BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
  • Homepage
  • Online Submission
Number of total visits
631925
Number of visits today
2
Number of downloads
308488
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Le Louedec F, Leenhardt F, Marin C, Chatelut É, Evrard A, Ciccolini J. Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. Vaccines (Basel) 2020;8:E632. [PMID: 33142728 DOI: 10.3390/vaccines8040632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Butner JD, Wang Z. Predicting immune checkpoint inhibitor response with mathematical modeling. Immunotherapy 2021;13:1151-5. [PMID: 34435504 DOI: 10.2217/imt-2021-0209] [Reference Citation Analysis]
2 Masters JC, Khandelwal A, di Pietro A, Dai H, Brar S. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma. CPT Pharmacometrics Syst Pharmacol 2022;11:458-68. [PMID: 35166465 DOI: 10.1002/psp4.12771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li N, Zhang X, Zhang Y, Yang F, Zhou F, Hashmi MF. Study of PD-1 Customization and Autoimmune T Cells for Advanced Colorectal Cancer with High MSI Expression. Contrast Media & Molecular Imaging 2022;2022:1-7. [DOI: 10.1155/2022/6390924] [Reference Citation Analysis]
4 Yadav D, Kwak M, Chauhan PS, Puranik N, Lee PCW, Jin JO. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Semin Cancer Biol 2022:S1044-579X(22)00044-X. [PMID: 35181474 DOI: 10.1016/j.semcancer.2022.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chatelut E, Hendrikx JJMA, Martin J, Ciccolini J, Moes DJAR. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacol Res Perspect 2021;9:e00757. [PMID: 33745217 DOI: 10.1002/prp2.757] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Marin C, Khoudour N, Millet A, Lebert D, Bros P, Thomas F, Ternant D, Lacarelle B, Guitton J, Ciccolini J, Blanchet B. Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals (Basel) 2021;14:796. [PMID: 34451893 DOI: 10.3390/ph14080796] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345